endo pharmaceuticals

iShares Dow Jones US Healthcare Provider (NYSE: IHF) is up more than 19% year to date. The fund invests at least 90% of its assets in securities of the underlying index, which measures the performance of the health care providers sector of the U.S. equity market. Top holdings include UnitedHealth...

PowerShares S&P SmallCap Health Care (NYSE: PSCH) is up nearly 22% year to date. The investment seeks to replicate the S&P SmallCap 600 Capped Health Care index, which is comprised of common stocks of U.S. health care companies. Top holdings include Regeneron Pharmaceuticals (NASDAQ: REGN...

Citi is out with its report today on Endo Pharmaceuticals (NASDAQ: ENDP), maintaining Buy. In a note to clients, Citi writes, "We rate the shares of Endo as Buy/High Risk (1H). We expect Lidoderm and the Opana/Opana ER franchise to continue to generate material cash flows for several years beyond...

Endo Pharmaceuticals (NASDAQ: ENDP) announced today topline results from a phase 2 study comparing the novel investigational drug axomadol against placebo in the treatment of patients with moderate to severe chronic low back pain. The results indicate that axomadol did not meet predetermined study...

Piper Jaffray is reiterating its Neutral rating and $44 PT on Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP). “On Friday, Endo announced the recall of two lots of legacy product Endocet (a combination of oxycodone and acetaminophen), as well as four lots of two generic products made by...

J.P. Morgan resumed coverage of Endo Pharmaceuticals (NASDAQ: ENDP) with an Overweight rating and a price target of $50. In a research report published today, J.P. Morgan states, "Due to the completion of J.P. Morgan's involvement in the transaction announced on April 11, 2011, we...

Citi is raising its estimates on Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) on the following elements: “1) An earlier acquisition close,” Citi writes. “2) A lower blended rate on debt (4.4% vs. prior 5.0% est.); 3) $400M retirement in existing Term A loans (TLA); 4) $170M smaller use of...

According to Citi, Endo Pharmaceuticals Holdings (NASDAQ: ENDP) price target is $48. Citi said that it arrives at its $48 price target for Endo based on a relative 2012 P/E multiple compared to the specialty pharmaceutical peer group. “Our relative P/E valuation assumes Endo trades at ~9.3x our...

According to Oppenheimer, Endo Pharmaceuticals (NASDAQ: ENDP) reported adjusted EPS of $1.00, ahead of our $0.98 estimate and the Street estimate of $0.99. Oppenheimer said that we highlight that ENDP reported total revenues of $560M (higher than our $530M estimate) driven by higher generic...

Citigroup has raised the price target on Endo Pharmaceuticals (NASDAQ: ENDP) from $42 to $48 and maintains its Buy rating.

Stifel Nicolaus is upgrading iStar Financial (NYSE: SFI) to Buy. It is also upgrading Newcastle Investment (NYSE: NCT) to Buy. It is increasing the target price on Endo Pharmaceuticals (NASDAQ: ENDP) to $53.00 from $45.00. Estimates are increased on iStar Financial and Newcastle Investment, and...

Oppenheimer is out with its report today on Endo Pharmaceuticals (NASDAQ: ENDP), raising its PT from $42 to $48. In a note to clients, Oppenheimer writes, "On 4/11, ENDP announced the ~$2.9B all-cash acquisition of med device manufacturer American Medical Systems (NASDAQ: AMMD). Of note, ENDP's...

Oppenheimer has raised the price target on Endo Pharmaceuticals (NASDAQ: ENDP) from $42 to $48 and maintains its Outperform rating.